Courtney D. DiNardo, MD, MSCE

Courtney D. DiNardo, MD, MSCE, is a professor in the Department of Leukemia, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center in Houston. She is an academic clinical researcher with a primary focus on individualized therapy and precision oncology for myeloid malignancies, including the optimal incorporation of genomics into standard risk assessments and treatment algorithms, the clinical evaluation of targeted therapeutics for molecularly defined patient subgroups, and designing and executing successful clinical trials.

Dr DiNardo has served an integral role in several highly influential trials involving IDH1, IDH2, and BCL2 inhibitors, which have led to the US Food and Drug Administration approval of 3 therapies for acute myeloid leukemia since 2017 (ie, the first-in-class IDH2 inhibitor enasidenib, the IDH1 inhibitor ivosidenib, and the BCL2 inhibitor venetoclax in combination with hypomethylating agents).